04:22 AM EST, 11/03/2026 (MT Newswires) -- Moberg Pharma (MOB.ST) secured a new patent in the US for an improved dosing regimen for MOB-015, a topical drug for onychomycosis or fungal nail infection. The patent from the US Patent and Trademark Office is projected to expire in December 2041, according to a Tuesday release. Patent applications in other markets are pending. The Swedish pharmaceutical company aims to run an additional phase 3 study to support a future approval from the US Food and Drug Administration.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.